Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 207

1.

Health-related quality of life and disability in patients with rheumatoid, early rheumatoid and early psoriatic arthritis treated with etanercept.

Picchianti-Diamanti A, Germano V, Ferlito C, Migliore A, D'Amelio R, Laganà B.

Qual Life Res. 2010 Aug;19(6):821-6. doi: 10.1007/s11136-010-9651-3. Epub 2010 Apr 6.

PMID:
20373036
2.

Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment.

Strand V, Sharp V, Koenig AS, Park G, Shi Y, Wang B, Zack DJ, Fiorentino D.

Ann Rheum Dis. 2012 Jul;71(7):1143-50. doi: 10.1136/annrheumdis-2011-200387. Epub 2012 Jan 17.

3.

Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.

Schiff MH, Yu EB, Weinblatt ME, Moreland LW, Genovese MC, White B, Singh A, Chon Y, Woolley JM.

Drugs Aging. 2006;23(2):167-78.

PMID:
16536638
4.

Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis.

Bae SC, Gun SC, Mok CC, Khandker R, Nab HW, Koenig AS, Vlahos B, Pedersen R, Singh A.

BMC Musculoskelet Disord. 2013 Jan 8;14:13. doi: 10.1186/1471-2474-14-13.

5.

Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response.

Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE Jr, Perfetto EM.

Am J Manag Care. 2002 Mar;8(3):231-40.

6.

Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability.

Baumgartner SW, Fleischmann RM, Moreland LW, Schiff MH, Markenson J, Whitmore JB.

J Rheumatol. 2004 Aug;31(8):1532-7.

PMID:
15290731
7.

Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry.

Martin WJ, Shim M, Paulus HE, Chaudhari S, Feng J, Elashoff D, Hahn TJ, Ranganath VK; RADIUS Investigators.

J Clin Rheumatol. 2014 Sep;20(6):301-5. doi: 10.1097/RHU.0000000000000152.

9.

Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis.

Mease PJ, Woolley JM, Singh A, Tsuji W, Dunn M, Chiou CF.

J Rheumatol. 2010 Jun;37(6):1221-7. doi: 10.3899/jrheum.091093. Epub 2010 Apr 15.

10.

Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo.

Mathias SD, Colwell HH, Miller DP, Moreland LW, Buatti M, Wanke L.

Clin Ther. 2000 Jan;22(1):128-39.

PMID:
10688396
11.

Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.

van der Heijde D, Klareskog L, Singh A, Tornero J, Melo-Gomes J, Codreanu C, Pedersen R, Freundlich B, Fatenejad S.

Ann Rheum Dis. 2006 Mar;65(3):328-34. Epub 2005 Aug 3.

12.

Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial.

van Riel PL, Freundlich B, MacPeek D, Pedersen R, Foehl JR, Singh A; ADORE Study Investigators.

Ann Rheum Dis. 2008 Aug;67(8):1104-10. Epub 2007 Jul 31.

PMID:
17666447
13.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

14.

Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial.

Gladman DD, Bombardier C, Thorne C, Haraoui B, Khraishi M, Rahman P, Bensen W, Syrotuik J, Poulin-Costello M.

J Rheumatol. 2011 Jul;38(7):1355-62. doi: 10.3899/jrheum.100698. Epub 2011 May 15.

15.

Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept.

Tanaka Y, Yamanaka H, Saito K, Iwata S, Miyagawa I, Seto Y, Momohara S, Nagasawa H, Kameda H, Kaneko Y, Izumi K, Amano K, Takeuchi T.

Mod Rheumatol. 2012 Apr;22(2):186-94. doi: 10.1007/s10165-011-0510-z. Epub 2011 Sep 8.

PMID:
21901357
16.

Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis.

Chen JS, Makovey J, Lassere M, Buchbinder R, March LM.

Arthritis Care Res (Hoboken). 2014 Mar;66(3):464-72. doi: 10.1002/acr.22151.

17.
18.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

19.

Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial.

Kirkham B, de Vlam K, Li W, Boggs R, Mallbris L, Nab HW, Tarallo M.

Clin Exp Rheumatol. 2015 Jan-Feb;33(1):11-9. Epub 2014 Dec 22.

PMID:
25535650
20.

Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens.

Gniadecki R, Robertson D, Molta CT, Freundlich B, Pedersen R, Li W, Boggs R, Zbrozek AS.

J Eur Acad Dermatol Venereol. 2012 Nov;26(11):1436-43. doi: 10.1111/j.1468-3083.2011.04308.x. Epub 2011 Oct 31.

PMID:
22035157

Supplemental Content

Support Center